CYP17A1

Across TCGA pan-cancer cohorts, CYP17A1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP17A1 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in testicular germ cell tumors (TGCT), where higher CYP17A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP17A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

TGCT, PRAD, and ESCA are the cancer types where CYP17A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
TGCT	DFS	Median	All	0.094	0.801	.008	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	DFS	Median	All	0.953	0.628	.039	2	view →
SKCM	DFS	Median	All	0.073	0.211	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP17A1–TGCT (DFS)

Open the TGCT breakdown →